Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligable to try a new drug.
A Second Opinion Leads to a New Treatment Plan
Brad Kerr changed his pancreatic cancer treatment plan after getting a second opinion, and had neoadjuvant chemotherapy before his Whipple.
I’ll Never Stop Fighting
When Lynne Holcomb was diagnosed with stage IV pancreatic cancer, she kept fighting through treatment and made it onto a clinical trial.
Questions to Ask Before You Begin Chemotherapy
Do you want to better understand your pancreatic cancer treatment? Dr. Andrew Hendifer outlines important questions to ask before starting chemotherapy.
New Study Focuses On Supportive Oncology Care At Home
For some newly diagnosed patients with borderline resectable tumors or locally advanced disease, neoadjuvant therapy is proving to be a…
A New Drug to Target Cancer Cell Enzymes
In patients with metastatic pancreatic cancer, researchers are comparing FOLFIRINOX, the standard treatment, with FOLFIRINOX plus CPI-613, a new drug…
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
A Clinical Trial for a Rare Pancreatic Cancer
Allison Lippman Kuban was trying to tolerate a difficult chemotherapy regimen when a mutation was found that qualified her for a clinical trial.
